Related Experiment Video
Updated: May 13, 2026
Fluorescent Orthotopic Mouse Model of Pancreatic Cancer
Published on: September 20, 2016
Evaluation of TRAM@PPF Nanoparticles for Efficacy Against Pancreatic Cancer in Mice Model
Ping Sheng1, Liang Zhang2, Wenwei Xie2
1Department of Oncology, Chongqing University Jiangjin Hospital, Chongqing, 402260, People's Republic of China.
Introduction:
Pancreatic ductal adenocarcinoma (PDAC) poses a major challenge due to the lack of effective treatment options and its extremely poor prognosis. Nanodrug delivery systems can improve drug solubility and enable efficient targeted delivery, offering new possibilities for PDAC therapy.
Methods:
The oncogenic role of KCa3.1 in PDAC was validated through analyses of The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) databases combined with functional assays. To overcome the limitations of conventional therapies, we developed a targeted nanodrug delivery system, TRAM@PPF, based on PLGA nanoparticles modified with polyethylene glycol-folate (PEG2000-FA). This system was prepared by the emulsion-solvent evaporation method to specifically deliver the KCa3.1 channel inhibitor TRAM-34 to PDAC cells. We characterized the nanosystem's physical properties and release profile and evaluated its antitumor efficacy in vitro and in vivo.
Results:
The synthesized TRAM@PPF nanoparticles demonstrated uniform size (~142 nm) and excellent stability, with superior cellular uptake compared to non-folate-modified nanoparticles. In vitro, TRAM@PPF showed potent antitumor activity by markedly inhibiting cell proliferation and enhancing apoptosis. Following intravenous administration in pancreatic cancer mouse models, TRAM@PPF significantly inhibited tumor growth, reduced tumor weight, and prolonged survival. Moreover, TRAM@PPF showed excellent biosafety in animal models, suggesting strong potential for further clinical translation in PDAC therapy.
Conclusion:
TRAM@PPF preserves folate-mediated tumor-targeting capability while significantly enhancing antitumor activity, offering a promising strategy for targeted therapy of pancreatic cancer.
Insights
A novel nanodrug delivery system, TRAM@PPF, effectively targets pancreatic ductal adenocarcinoma (PDAC) cells. This system demonstrated significant antitumor activity and improved survival in preclinical models, offering a promising new therapeutic strategy for PDAC.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis and limited treatment options.
- Nanodrug delivery systems offer potential for improved drug solubility and targeted delivery in PDAC therapy.
Purpose of the Study:
- To develop and evaluate a targeted nanodrug delivery system, TRAM@PPF, for PDAC therapy.
- To investigate the in vitro and in vivo antitumor efficacy and biosafety of TRAM@PPF.
Main Methods:
- Validated the oncogenic role of KCa3.1 in PDAC using TCGA and GTEx databases and functional assays.
- Developed TRAM@PPF nanoparticles (PLGA nanoparticles modified with PEG-folate) for targeted delivery of TRAM-34.
- Characterized nanoparticle properties and evaluated antitumor efficacy in vitro and in vivo models.
Main Results:
- TRAM@PPF nanoparticles exhibited uniform size (~142 nm), excellent stability, and enhanced cellular uptake.
- In vitro studies showed potent inhibition of cell proliferation and enhanced apoptosis.
- In vivo studies demonstrated significant tumor growth inhibition, reduced tumor weight, and prolonged survival in pancreatic cancer mouse models.
Conclusions:
- TRAM@PPF nanoparticles effectively target PDAC cells via folate-mediated mechanisms.
- The TRAM@PPF system shows significant antitumor activity and excellent biosafety, indicating strong potential for clinical translation in PDAC therapy.
More Related Videos
06:57Utilizing High Resolution Ultrasound to Monitor Tumor Onset and Growth in Genetically Engineered Pancreatic Cancer Models
Published on: April 7, 2018
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
